常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.30/--
|
|
企业价值
--
|
| 资产负债 |
|
每股账面净值
不适用
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Aspen Neuroscience Inc is a clinical-stage, regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to initially address neurodegenerative diseases with high unmetmedical need. The company's flagship program, sasineprocel, is an investigational autologous iPSC-based therapy for Parkinson's disease designed to replace a patient's lost dopamine neurons with dopaminergic neuron precursor cells. |

-- 
